Avanafil

Drug Profile

Avanafil

Alternative Names: Spedra; Stendra; TA-1790; Zepeed

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Endo International; JW Pharmaceutical; Menarini; Sanofi; VIVUS
  • Class Erectile dysfunction therapies; Pyrimidines; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Erectile dysfunction; Erectile dysfunction

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Female sexual dysfunction; Premature ejaculation

Most Recent Events

  • 05 Oct 2016 Avanafil licensed to Metuchen Pharmaceuticals for commercialisation in USA, Canada, South America and India
  • 09 May 2016 VIVUS has patent protection for avanafil in USA
  • 01 Mar 2016 Sanofi completes a phase III trial in Erectile dysfunction in Russia (PO) (NCT02503306)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top